IPOs are great for either shorting or loading the boat depending on the pricing and the pitch. How do you know which to do? That is what we asked for years when we started investing in the markets and soon grew to understand and know. That is why you come to us right, to get the facts to help provide you the profitable tools to make educated decisions. While we wish we could boast a sure thing but that is about as possible as the Dow Jones hitting 20,000 in 2010 that is why we too evaluate the research available and then trust our gut to swing us in the right direction.

Through our friends on Seeking Alpha here are 7 IPOs to look for this week with the key points:

Ambow Education Holding (AMBO), which provides education, test prep and IT career training services in China, plans to raise $117 million by offering 10,677,210 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, Ambow Education Holding will command a market value of $844.24 million. Ambow Education Holding, which was founded in 2000, booked $146 million in sales over the last 12 months. The Beijing, China-based company plans to list on the NYSE under the symbol AMBO. J.P. Morgan (JPM), Goldman Sachs (Asia) L.L.C. (GS) are the lead underwriters on the deal.

D. Medical (DMED), a medical device company that develops and manufactures insulin pumps, plans to raise $30 million by offering 2,727,273 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, D. Medical will command a market value of $98.33 million. D. Medical, which was founded in 1992, booked $0 million in sales over the last 12 months. The Ramat Gan, Israel-based company plans to list on the NASDAQ under the symbol DMED. Rodman & Renshaw (RODM), ThinkEquity are the lead underwriters on the deal.

Gordmans Stores (GMAN), an everyday low price fashion retailer operating 68 stores in the Midwest, plans to raise $75 million by offering 5,357,143 at a price range of $13.00 to $15.00. At the mid-point of the proposed range, Gordmans Stores will command a market value of $261.84 million. Gordmans Stores, which was founded in 1915, booked $458 million in sales over the last 12 months. The Omaha, NE-based company plans to list on the NASDAQ under the symbol GMAN. Piper Jaffray (PJC), Wells Fargo Securities (WFC) are the lead underwriters on the deal.

IntraLinks Holdings (IL), which provides secure online document management to over 4,300 customers, plans to raise $165 million by offering 11,000,000 at a price range of $14.00 to $16.00. At the mid-point of the proposed range, IntraLinks Holdings will command a market value of $766.70 million. IntraLinks Holdings, which was founded in 1996, booked $141 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol IL. Morgan Stanley (MS), Deutsche Bank Securities (DB), and Credit Suisse (CS) are the lead underwriters on the deal.

NuPathe (PATH), a specialty pharma seeking approval for Zelrix, a patch for migraine treatment, plans to raise $75 million by offering 5,000,000 at a price range of $14.00 to $16.00. At the mid-point of the proposed range, NuPathe will command a market value of $211.68 million. NuPathe, which was founded in 2005, booked $0 million in sales over the last 12 months. The Conshohocken, PA-based company plans to list on the NASDAQ under the symbol PATH. Leerink Swann, Lazard Capital Markets (LAZ) are the lead underwriters on the deal.

NXP Semiconductors (NXPI), a diversified global semiconductor company and former carve-out of Philips, plans to raise $663 million by offering 34,000,000 at a price range of $18.00 to $21.00. At the mid-point of the proposed range, NXP Semiconductors will command a market value of $4,860.40 million. NXP Semiconductors, which was founded in 1953, booked $3,843 million in sales over the last 12 months. The Eindhoven, Netherlands-based company plans to list on the NASDAQ under the symbol NXPI. Credit Suisse, Goldman, Sachs & Co., and Morgan Stanley are the lead underwriters on the deal. Please note: *Filed with SEC under KASLION Acquisition B.V.

SurgiVision (SRGV), which has developed an MRI-guided device for minimally invasive brain procedures, plans to raise $25 million by offering 2,500,000 at a price range of $13.00 to $15.00. At the mid-point of the proposed range, SurgiVision will command a market value of $111.01 million. SurgiVision, which was founded in 1998, booked $3 million in sales over the last 12 months. The Memphis, TN-based company plans to list on the NASDAQ under the symbol SRGV. Canaccord Genuity (CCDPF.PK), Rodman & Renshaw are the lead underwriters on the deal. Please note: *Lowered range to $9-$11 (was $13-$15) [Update: IPO is now postponed.]

Trius Therapeutics (TSRX), which is developing an antibiotic for serious gram-positive Staph infections, plans to raise $78 million by offering 6,000,000 at a price range of $12.00 to $14.00. At the mid-point of the proposed range, Trius Therapeutics will command a market value of $216.82 million. Trius Therapeutics, which was founded in 2004, booked $5 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol TSRX. Citi (C), Piper Jaffray, and Canaccord Genuity are the lead underwriters on the deal. Please note: *Previously postponed on 3/1/2010 due to modification of its Ph. 3 trials, refiled amendment on 6/16/2010.

Last week, there were 3 IPO pricings. Envestnet (ENV), which provides outsourced web-based investment solutions to financial advisors, was the week’s winner, ending up 12% from its IPO price.

As always we will post our latest stock, IPO information and links on Twitter and will provide our weekly

We always believe some of the best investment advice comes from looking at those that are successful around us. The same reason you come to us to find out relative profitable information to help you find the right investments, we also do this by scanning the industry and the experts in the fields and more specifically those that are making ungodly amounts of money.  Case in point….

With the help of our Fool peers here is a quick look at the stocks making it into Warren Buffet’s portfolio.

When it comes to investing, there’s a heck of a lot that Buffett can do that I simply can’t. For instance, back in the fear-filled days of 2008, he wrangled preferred stock yielding 10% from both Goldman Sachs and General Electric (NYSE: GE). He’s also been able to snatch up great privately held companies like See’s Candies and swallow whole public companies such as Burlington Northern Santa Fe. Such is the benefit of a sterling reputation, an eye for bargains, and a massive balance sheet.

But when it comes to common stocks, I can go after the exact same shares that Buffett is buying for Berkshire. And when it comes to one stock in particular, I am most definitely on the same page as Buffett. It’s Berkshire’s largest stock holding. It’s a staple among consumer staples. It is, of course, Coca-Cola (NYSE: KO).

Here are some similar stocks like Coca-Cola that we agree have the merits for us to buy and hold on to.

1. Altria (NYSE: MO) and Philip Morris International (NYSE: PM) may leave a bad taste in some investors’ mouths (no pun intended) since their business is slinging tobacco products. But as far as finding a business with a rock star of a product at its core, these two companies may out-Coke Coke. In the U.S. the Marlboro brand commands an amazing 42% of the cigarette market, and internationally it’s been the top brand since 1972. Marlboro’s 302 billion cigarettes sold internationally in 2009 beat the next three competitors combined.
2. Diageo (NYSE: DEO) could likewise be categorized as “sin stock,” but I’d prefer to categorize it as simply sinfully successful. Just as nothing needs to be done to keep the Coke product successful, Diageo doesn’t need to do much to keep leading brands like Smirnoff, Johnnie Walker, Guinness, Captain Morgan, and Jose Cuervo — to name a few — trucking along. Motley Fool Income Investor advisor James Early recently made Diageo his pick for The Motley Fool’s “11 O’Clock Stock” series, largely because of its amazing brand portfolio.
3. Procter & Gamble (NYSE: PG) doesn’t have a single product that provides the foundation of the company, but instead it has large portfolio of products. P&G does more tweaking to its products than Coke — think about the changes to Gillette razors or innovations for Pampers diapers — but brands like Tide, Vicks, Oral-B, Scope, Zest, and Old Spice don’t need significant technological advancements to keep the dollars rolling in.